Physician profile
Andre C Eaddy
NPI 1003251166
$212,242.36
in general payments reported to CMS, 2019-2025
36 companies · $169K in 2025
The $169K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $375 · 2021: $108 · 2022: $5,410 · 2023: $17K · 2024: $20K · 2025: $169K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $175K · Travel and Lodging: $18K · Food and Beverage: $11K · Consulting Fee: $2,875 · Education: $33.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $175,001.58 |
| Travel and Lodging | $17,671.65 |
| Food and Beverage | $10,767.08 |
| Consulting Fee | $2,875.00 |
| Education | $33.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $76,876.69 | 2020-2025 | Rinvoq, Skyrizi, Creon |
| Janssen Biotech, INC. | $75,997.46 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $52,201.15 | 2024-2025 | Omvoh |
| Genzyme Corporation | $3,019.83 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $635.12 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Celltrion USA INC. | $291.51 | 2024-2025 | Vegzelma, Zymfentra |
| Madrigal Pharmaceuticals | $284.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Erbe USA INC | $268.75 | 2024-2025 | Vio3, Vio3 Apc3 |
| Regeneron Healthcare Solutions, INC. | $244.91 | 2024-2025 | Dupixent |
| Qol Medical, LLC | $221.01 | 2020-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $215.35 | 2024-2025 | |
| Ardelyx, INC. | $210.92 | 2023-2025 | Ibsrela |
| Pfizer INC. | $204.61 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.26 | 2020-2025 | Xifaxan |
| Olympus America INC. | $162.34 | 2020-2025 | Single Use Repositionable Clip |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Eaddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.